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Abstract
Activation of oncogenes is generally associated with the induction of DNA damage response (DDR) signaling,
which acts as a barrier to tumor progression. In this review we will present an overview of the DDR associated
with oncogenic activation of Myc, with special focus on two opposite and paradoxical aspects of this response: (1)
the role of the Myc-induced DDR in tumor suppression; (2) its role in dampening Myc-induced replication stress,
thereby protecting the viability of prospective cancer cells. These opposing effects on cancer progression are
controlled by two different branches of DDR signaling, respectively ATM/CHK2 and ATR/CHK1. Indeed, while ATM
activity constitutes a barrier to malignant transformation, full activation of ATR and CHK1 is essential for tumor
maintenance, providing important opportunities for therapeutic intervention. Thus, the Myc-induced DDR acts as a
double-edged sword in tumor progression.
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c-MYC
c-MYC (henceforth MYC) is an immediate-early serum
response gene essential for embryonic development, cel-
lular proliferation and survival, and a cellular proto-onco-
gene that is frequently up-regulated in cancer. The Myc
protein is a basic Helix-Loop-Helix Leucine Zipper
(bHLHZip) transcription factor, which forms transcrip-
tionally active dimers with another bHLHZip protein
called Max [1,2]. Dimerization with Max endows Myc
with sequence specific DNA binding ability, preferentially
to sites containing the E-box sequence CACGTG. The
transactivation properties of this complex are carried out
by the N-terminal portion of Myc [3]. Myc is a multi-
functional transcription factor able to regulate cell cycle,
growth, metabolism, differentiation, apoptosis, transfor-
mation, genomic instability, and angiogenesis. Recently,
transcription independent functions of Myc have been
proposed particularly concerning the role of Myc in regu-
lating pre-replication complexes assembly onto DNA
replication origins [4]. While low Myc levels are neces-
sary and sufficient for cellular viability and proliferation,
pathological activation of this proto-oncogene has been
linked to over-expression and gain of function mutations
[5-7]. Pathological over-expression is frequently achieved
by transcriptional up-regulation due to chromosomal
translocation leading to promoter rearrangement [8-12],
gene amplification [13,14] or by virus mediated inser-
tional mutagenesis [15,16]. In prostate and breast can-
cers, a significant fraction of tumors demonstrate
amplification of an otherwise unrearranged c-MYC locus
(Pietilainen et al., 1995; Bubendorf et al., 1999; Sato et al.,
1999; Naidu et al., 2002). In contrast, the Myc mRNA
and protein over-expressiont h a ti so b s e r v e di n7 0 - 8 0 %
of colon carcinomas (Smith and Goh, 1996) results from
aberrant transcriptional control of the MYC locus invol-
ving mutations in APC-b-catenin-TCF-4 pathway mem-
bers (Barker et al., 2000). Similarly, in Human acute
T-cell lymphoblastic leukemias and lymphomas (T-ALL)
gain-of-function mutants of Notch1 ensure robust tran-
scriptional activation of MYC [17]. Besides, during tumor
progression the Myc protein is often stabilized, either
because it acquires specific point mutations [18] or
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ways such as RAS [19] or AKT [20].
Myc activation elicits cell intrinsic tumor suppressive
mechanisms
1. The ARF/MDM2/p53 pathway
A direct consequence of Myc over-expression is a
hyper-proliferative response, which is generally counter-
balanced by the activation of intrinsic tumor suppressive
mechanisms that effectively restrain clonal expansion of
pre-cancerous cells. These mechanisms often arise as
intracellular responses to stress situations directly
induced by Myc. The best characterized arm of Myc-
induced tumor suppression relies on the ARF/MDM2/
p53 pathway, which results in the activation of a p53
dependent apoptotic response [21-23] (Figure 1). This
p a t h w a yi sc o n t r o l l e db yA R F ,an u c l e o l a rp r o t e i n ,
encoded by the INK4a/ARF locus, that is able to bind
MDM2, a ubiquitin ligase that in turns ubiquitylates p53
and dooms it for proteasomal degradation. Thus this
pathway is epistatically regulated by ARF levels: in nor-
mal conditions ARF is undetectable, while upon Myc-
induced oncogenic stress its locus is transcriptionally
activated, resulting in p53 stabilization and activation.
Mouse model have been instrumental to the genetic dis-
section of the ARF/MDM2/p53 pathway and the charac-
terization of the p53 effector functions required for
tumor suppression, which, especially in hematopoietic
malignancies rely largely, but not exclusively [24], on
p53 dependent apoptosis [25,26].
2. The myc-induced DNA damage response
The ARF/MDM2/p53 pathway is not the only tumor
suppressive tool available to cell for restraining the onco-
genic activities of Myc. More recently, the DNA damage
response (DDR) has also been shown to act as an ARF-
independent hurdle that limits aberrant cell division in
early tumorigenesis [27-29]. Although it is still not com-
pletely clear what type of physical alterations are induced
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Figure 1 Myc induced tumor suppressive pathways. Outline of the p53 dependent pathways involved in Myc induced tumor suppression.
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mise that at least two types of DNA damage can be asso-
ciated with Myc overexpression. First, the production of
reactive oxygen species (ROS), which have been shown
to increase in experimental conditions where Myc is
deregulated, can increase oxidative damage [30]. Indeed,
the accumulation of ROS-associated oxidative damage
coincided with transient MYC activation in human fibro-
blasts cultured in vitro in low serum (0.05%) and/or
ambient oxygen tension [31]. To this end, it is worth
mentioning that while anti-oxidants can reduce the Myc-
induced DDR, their anti-tumoral activity has been mainly
ascribed to their ability to affect the HIF1a pathway [32].
Another possible source of Myc-induced DNA damage is
replication stress, a term used to define the generation of
aberrant DNA replication intermediates which lead to
the accumulation of DDR markers at sites of active DNA
replication. The Myc-induced DDR accounts for the
genomic and chromosomal instability frequently asso-
ciated with Myc hyper-activation. Indeed, a number of
chromosomal abnormalities including translocations,
dicentric chromosomes and tetraploidy have been
observed upon Myc overexpression [33]. Recent work
has allowed the charting of the relevant pathways regulat-
ing Myc-induced DDR, leading to the identification of
ATM [27,28,34], WIP1 [35] and TIP60 [29] as mediators
of this response (Figure 1). ATM encodes a phosphatidy-
linositol-3-kinase-like protein kinase which is the apical
kinase responsible for the activation of DDR following
DNA double strand breaks (DSBs) accumulation. It phos-
phorylates and activates numerous substrates upon DNA
damage, such as the diffusible kinase CHK2, which is
required for proper cellular amplification of the DSBs
induced DDR, and the p53 protein, the key effector of
the DDR. Once phosphorylated, p53 escapes the deadly
embrace of MDM2, ensuring a prolonged G2 arrest, the
induction of DNA repair and, depending on the extent of
DNA damage and on the cell type, stimulating either
apoptosis or senescence [36]. Circumstantial evidence
suggested a link between Myc and ATM, since ATM
-/-
thymic lymphomas developing in mice ATM
-/- are fre-
quently characterized by extra copies of chromosome 15,
w h e r et h ec - m y cg e n em a p s[ 3 7 ] .A l s o ,o n c o g e n i cM y c
activation has been associated with ATM inactivation in
different human tumors, including B-cell lymphomas
[38]. More direct evidence comes from a number of
genetics studies in mouse models of Myc-induced tumor-
igenesis, such as the Eμ-myc transgenic mouse, which is
predisposed to develop B-cell tumors with high pene-
trance [39]. In this genetic background, both DDR and
apoptosis induced by Myc were reduced upon ATM loss,
while tumorigenesis was markedly accelerated. Of rele-
vance, ATM loss did not abolish the strong selective
pressure to inactivate p53 or ARF, highlighting that ATM
controls p53 independently from ARF [27,34]. The role
of ATM in regulating Myc-induced tumor suppressive
DDR, was also confirmed in a mouse model of skin can-
cer suggesting that the relevance of this pathway in sup-
pressing Myc-induced tumors suppression is not
restricted to hematological malignancies, but extends to
solid tumors [28]. These results were extended by the
genetic analysis of mice lacking WIP1 a protein phospha-
tase that negatively regulates ATM, with loss of WIP1
protecting against Eμ-Myc induced lymphomas [35].
WIP1 loss, not only abolished the genetic pressure for
ARF loss of heterozygosity in tumors that developed in
Eμ-myc;ARF
-/+;WIP1
-/- mice, but also prevented tumor
development in Eμ-myc;ARF
-/- mice. Yet, tumor suppres-
sive responses were still completely dependent on p53.
Thus the lack of WIP1 potentiates p53 dependent tumor
suppression to a level sufficient to protect B-cells from
Myc-induced lymphomagenesis, even in the absence of
functional p19
ARF. The enhanced tumor suppression
conveyed by WIP1 loss was only partially bypassed by
ATM loss, arguing for a more pleiotropic effect of WIP1
compared to ATM. Similar results were reported for the
haploinsufficient tumor suppressor TIP60 [29], a histone
acetyl transferase (HAT) that has been implicated in the
regulation of the DDR via activation of ATM [40] and of
DNA repair through the catalytic subunit of the NuA4
complex, a multifunctional complex with HAT and chro-
matin remodeling activities. The NuA4-Tip60 complex is
recruited to DSBs, where it acetylates histones H2AX
and H4, facilitating both turnover of H2AX and modify-
ing chromatin architecture to allow DSB repair [41-43].
In the Eμ-myc transgenic mouse, TIP60 is a haploinsuffi-
cient tumor suppressor required for an efficient Myc-
induced DDR. Loss of one TIP60 allele blunted ATM
activation, p53 phosphorylation on Serine 18 and H2AX
phosphorylation, resulting in a dramatic acceleration of
tumorigenesis, while the activation of the ARF-p53
tumor suppressor pathway or the resulting apoptotic
responses were unaffected. The occurrence of TIP60
mutations in human tumors and its parallel loss of
expression in advanced stages of different cancer types
suggested that mechanism of tumor suppression
described in animal models are also relevant in human
pathologies [29].
Therapeutic implications of the evasion of DDR
dependent tumor suppressive responses
The existence of tumor suppressive pathways evoked by
the DNA damage response and their obligatory inactiva-
tion during tumor progression may have important ther-
apeutic implications since some tumors may accumulate
mutations in the DDR pathways in order to escape
tumor suppression. These DDR defective tumors will be
refractory to all the therapeutic regimens that require a
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dard chemotherapy protocols [34]. On the other hand,
tumors that are defective in some effector functions of
the DDR may offer the opportunity for pharmacological
targeting of specific branches of the DDR that are other-
wise compensated in normal cells and tissues. This con-
cept of synthetic lethality has been exploited for the
rationale use of Poly (ADP-ribose) polymerase (PARP)
inhibitors which generate replication dependent DNA
double-strand breaks (DSBs) that are irreparable in
BRCA1/2 defective cells thus effectively killing tumors
[44]. Another example is represented by DDR check-
point defective cells, which may be more sensitive to
DNA repair inhibitors. In fact, CHK2 inactivation,
which may be selected for during Myc-induced tumor
progression may render cells more prone to DNA repair
inhibition as shown in the case of Myc-induced tumors,
where CHK2 loss shows a synergistic lethal response in
combination with DNA repair inhibitors such as PARP
inhibitors [45]. Also, mutations accumulated in DDR
pathways during tumor development reduce the options
available to a cell to respond to DNA damage thereby
potentially exposing tumor cells to the inhibition of
pathways that may be otherwise be compensated in nor-
mal cell. This concept is exemplified by the observation
that ATM deficient cells are sensitized to the chemical
and genetic inhibition of the ATR/CHK1 pathways,
although in vivo validation of this concept in preclinical
models is missing [46].
The concept of oncogene induced replicative stress (OI-
RS)
Oncogene induced replication stress has been recently
recognized has a major component of the oncogenic
stress response. Although still poorly characterized in
terms of mechanism, replication stress is often asso-
ciated with oncogene induced DDR (OI-DDR) [47].
Oncogenes such as Ras are capable of mounting strong
proliferative responses that are frequently associated
with elevated DDR activation. This association is parti-
cularly strong at the early stages of tumor progression
in line with the hypothesis that OI-DDR represents a
tumor suppressive response [47]. Several evidences lead
to surmise that a strong component of the DDR activa-
tion relies on DNA damage triggered by replication
stress [48,49]. First of all OI-DDR can be mimicked by
over-expression of key regulators of the cell cycle
machinery, such as cyclin E, whose activity peaks at the
beginning of S-phase and in many systems contributes
to S-phase progression, Cdc6 which is involved in repli-
cation origin licensing, the Cdc25 phosphatase, a posi-
tive regulator of all the cyclin/CDK complexes that are
activated during S-phase, or E2F1. Second, in cellular
models, over-expression of oncogenes leads to the
accumulation of a DDR that depends on progression
through S-phase: if DNA synthesis is pharmacologically
blocked, then DDR activation is blunted. In addition,
fragile sites, which represent genomics sites known to
be prone to accumulate mutations during DNA replica-
tion, are hot spots for DNA mutations upon oncogene
induced replication stress. Finally, the observation that
H2AX phosphorylation and PCNA co-localize with sin-
gle stranded DNA strongly suggest that a primary
source of OI-DNA damage is generated at replication
forks. All these evidences collectively suggest that OI-
DDR is largely due to replicative stress.
Myc ensures proliferative advantage by coping with
replicative stress
As observed with many oncogenes, Myc over-expression
brings about a certain level of replication stress documen-
ted by the generation of DDR markers in S-phase cells that
co-localize with active replication forks. Yet, contrary to
other oncogenes, Myc activation provides long-term prolif-
erative advantage, thus suggesting that the anti-proliferative
effects triggered by RS and DDR may be mitigated by Myc
itself. In fact several evidence that will be presented below
suggest that while unrestricted activation of Myc can gen-
erate replication stress, Myc also controls several pathways
that actively restrain the extent of replication stress to
allow proficient cellular proliferation (Figure 2).
1. Myc-induced DNA replication
The ability of Myc to promote cellular proliferation
stems from its ability, as a transcription factor, to
directly control the expression of a large number of cel-
lular pathways implicated in S-phase progression [50].
In addition, rather unexpectedly, Myc itself can localize
onto sites of active DNA replication suggesting a more
direct role of Myc in controlling S-phase progression
possibly by directly participating in licensing or assem-
bly of (pre)-replicative complexes [4]. Alternatively, the
pervasive Myc binding to the genome, especially when
over-expressed, and its strong transcriptional activity
may contribute to the activation of latent replication ori-
gin by making them more accessible to replication fac-
tors. Therefore we can envision Myc promoting S-phase
either by transcriptionally regulating the cell cycle
machinery, the nucleotide biosynthetic pathways and by
directly affecting the number of active replication forks.
2. How is myc-induced DDR activated during DNA
replication?
We propose three alternative explanations, not necessa-
rily mutually exclusive, as to how DDR is activated dur-
ing S-phase in cells expressing elevated Myc levels. The
first possibility is that the increased number of active
origins and the increased global S-phase progression
rate may raise the level of DNA damage physiologically
accumulated during DNA synthesis. Alternative, the
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ity may generate the physical clashing of the RNA poly-
merase along with the DNA replication machinery
thereby causing replication fork collapse and consequent
activation of a DDR. Indeed, the co-localization of Myc,
replication complexes and DDR factors onto DNA dur-
ing S-phase, may be an indication that this situation
happens in vivo. Lastly, DNA damage may be generated
because of fork instability due to metabolic starvation,
since despite Myc’s ability to boost purine and pirimi-
dine metabolism [51], this may not completely satisfy
the high demand of nucleotides needed during hyper-
proliferative S-phase.
3. Myc overexpressing cells balance replication stress with
S-phase progression
Despite evidences of a replication stress response in Myc
over-expressing cells, a number of observations suggest
that indeed elevated levels of Myc trigger also compensa-
tory responses able to effectively reduce, but not comple-
tely eliminate, the consequences of replication stress.
Here we provide some examples.
WRN helicase The first example is represented by WRN,
ag e n ee n c o d i n gaR e c QD N Ah elicase, which is found
mutated in Werner Syndrome, a disease characterized by
cellular senescence, increased chromosomal instability
characterized by frequent chromatid breaks, and acceler-
ated aging [52]. The WRN helicase resolves topologically
unfavorable DNA structures that form during S-phase,
such as those arising at stalled replication forks, therefore
representing a bona fide factor endowed with anti-repli-
cation stress activity [53]. MYC exacerbates this function
of WRN, since its over-expression in WRN-/- fibroblasts
leads to excessive accumulation of DNA damage at sites
of newly replicated DNA [54]. This elevated DNA
damage triggers the activation of the ATR-CHK1 path-
way, resulting in a strong anti-proliferative, senescent
response. Since WRN is a transcriptional target of MYC,
up-regulation of the WRN gene represents a feed-for-
ward mechanism to limit MYC-associated replication
stress thus allowing continued cellular proliferation [55].
Grandori and coworkers also addressed the role of WRN
in Myc associated cancer in xenografts experiments using
a non-small cell lung carcinoma cell line expressing high
levels of Myc (A549, NSCLC) where WRN was silenced
by RNA knock-down. They also used a classic genetic
approach breeding a cohort of Myc transgenics for
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Figure 2 How Myc deals with intrinsic replication stress. Schematic representation of the pathways engaged by Myc to counteract intrinsic
replicative stress responses that would limit clonal expansion of (pre)-cancerous cells.
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Page 5 of 10Eμ-myc with mice carrying a germline mutation of WRN
(Wrn
Δhel/Δhel). In both cases tumor growth was signifi-
cantly delayed, and as predicted, WRN loss of function in
the context of robust Myc activation led to the elevation
of a DNA damage response resulting in cellular senes-
cence and tumor necrosis [56].
Nucleotide synthesis Another trick Myc may pull off to
counteract replication stress is increasing the rate of
nucleotide synthesis. As already discussed, oncogenes
are able enforce cell proliferation leading to replication
perturbation, DNA damage accumulation and genome
instability. This replication stress is at least in part due
to the high rate of DNA synthesis which is not properly
fuelled by the biosynthetic pathways that provide purine
and pyrimidine nucleotides. In in-vitro experiments, an
exogenous supply of nucleosides was shown to rescue
replication stress, to decrease replication-induced DNA
damage, and to reduce transformation of cells expres-
sing viral or cellular oncogenes [57]. Shortage of intra-
cellular nucleotides not only affects replication dynamics
but can also modulate origin firing and licensing.
Indeed, under chronic exposure to a low-nucleotide
pool, cells have been shown to compensate for DNA
replication stress by increasing origin density during G1.
Recently, it was demonstrated that c-Myc is an impor-
tant regulator of nucleotide biosynthesis and that its
expression elevates nucleotide levels and cell prolifera-
tion [51,58]. This was experimentally validated, since
STOP  GO 
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Replicative Stress  Checkpoint-Apoptosis 
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Figure 3 Dual nature of Myc induced DDR. Tumor promoting DDR: Myc engages the replication checkpoint pathway (ATR/CHK1) to allow
robust cellular proliferation and avoid cytotoxic DNA damage accumulation. Tumor suppressive DDR: Myc induced DNA damage response
triggers tumor suppressive pathways that act as a barrier to malignant transformation.
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was significantly rescued by co-expression of c-Myc.
Thus, the Myc-induced increase in nucleotide pool size
can be regarded as an effective mechanism to rescue
cells experiencing replication stress and to prevent DNA
damage accumulation during S-phase.
The ATR/CHK1 pathway Another pathway that is con-
trolled by Myc and is involved in the replication stress
response is the ATR/CHK1 pathway. This pathway is
activated by Replication Protein A (RPA)-coated single
stranded DNA (ssDNA), which can be produced during
replication stress, DSBs resection, repair of DNA base
adducts or DNA crosslinks [59,60]. The most common
signal for ATR activation probably involves intrinsic
replication stress in every S-phase and perhaps regulation
of specific aspects of DNA replication such as origin fir-
ing or nucleotide production. As such, the ATR kinase
and CHK1, are essential genes whose homozygous germ-
line mutation compromises cellular viability and embryo-
nic development [61-63]. The ATR gene encodes a large
ATM-related protein kinase, which is recruited at sites of
ssDNA along with ATRIP and is activated by the pre-
sence of accessory factors such as Claspin and TopBP1.
Homozygous mutations affecting the splicing of the ATR
mRNA have been identified in patients with the rare
Seckel syndrome, a disease characterized by microce-
phaly and growth retardation. A mouse model recapitu-
lating this mutation (ATR
s/s) has confirmed its causality
in determining the etiology of the disease, since ATR
s/s
mice displayed accelerated aging, microcephaly, growth
retardation and pervasive replication stress during
embryonic development [64]. The other key component
of this pathway is CHK1, a soluble checkpoint kinase
activated directly by ATR, which contributes to the trans-
duction of the DDR signals to activate effector functions
of the pathway, such as the S and the G2 checkpoint.
Other essential properties of CHK1 reside in its ability to
regulate replication fork progression, regulation of
nucleotide synthesis and anti-apoptotic activity [59,60].
Recent evidences have shown that the ATR/CHK1 path-
way has a gatekeeping function essential to restrain repli-
cation stress in cells with activated oncogenes. In fact
elevated levels of Myc sensitize a variety of cell types to
chemical inhibition of either CHK1 or ATR, by exacer-
bating a strong DDR that triggers a potent apoptotic
response [65-70].
Exploiting replication stress to design novel anti-cancer
therapies
The observation that Myc restrains intrinsic replicative
stress responses by activating specific pathways has rele-
vant implications from a therapeutic standpoint and
holds the promise of prospective clinical applications.
Indeed emerging evidences from recent in vivo studies
suggest a potential anticancer effect achieved by specific
targeting of the ATR/CHK1 pathway [65-70] or the
WRN helicase [56]. Genetic experiments in mouse mod-
e l so fM y c - i n d u c e dt u m o r i g e n e s i ss u c ha sE μ-myc
crossed with the ATR
s/s hypomorphic mutant unveiled a
profound role of ATR in preventing inherent replication
stress. In particular, a homozygous ATR
s/s background
resulted in complete protection against lymphomagenesis
[65]. A corollary of this synthetic interaction was the
observation that, in ATR
s/s animals, even non lymphoid
tissues with mild elevation of Myc levels (due to the lea-
kiness of the Eμ-myc transgene during development)
showed a pervasive RS that resulted in accelerated sys-
temic aging and reduced life span. Consistent with the
above results, systemic administration of the CHK1 inhi-
bitor UCN01 in mice bearing fully blown lymphomas
triggered a potent DDR response, cell cycle arrest and
widespread apoptosis. Continuous administration of
UCN01, or other CHK1 inhibitors, was able to cause fast
regression of established lymphomas, thus indicating the
therapeutic efficacy of targeting the ATR/CHK1 pathway.
Unfortunately, the low solubility of available ATR inhibi-
tors has so far limited their assessment in preclinical
mouse models. These observations were confirmed by
Nilsson and coworkers in a different mouse model of
Myc-induced lymphomas [66]. Also, a functional RNAi
screen in neuroblastoma cell lines that over-express N-
Myc has recently led to the identification of CHK1 as a
potentially therapeutic target [70]. In this study, sensitiv-
ity to CHK1 inhibition or knock-down positively corre-
lated with N-Myc protein levels. Also, while CHK1
inhibition had little effect in primary non-transformed
cells, the same cells modified to express high levels of N-
Myc were highly sensitive to the treatment. Thus, CHK1
inhibition strategies represent a promising therapeutic
option for the treatment of Myc-associated tumors.
Concluding remarks
We have here discussed two opposing functions of Myc-
induced DDR, which are relevant during pathological
activation of Myc. First, the DDR exerts a tumor suppres-
sive response that involves ATM, TIP60 and WIP1,
resulting in the activation of p53. This effect of the DDR
thus relies on p53 in order to restrains tumor develop-
ment. As such, this represents the classical concept of
OI-DDR generally associated with oncogene activation.
The second function of the Myc-induced DDR involves
the ATR/CHK1 pathway and has a completely different
biological consequence, since it is part of the proto-onco-
genic program that is activated in Myc overexpressing
cells. This tumor promoting DDR, activated to support
rather than suppress tumor development, acts to keep in
a latent state tumor suppressive responses that would be
otherwise toxic to cancer cells. This is one example of a
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tumor suppressive responses: others are represented by
the need for cancer cells to have high levels/activity of
specific Cyclin/Cdk complexes [71-74]. This rewiring of
(pre)-cancerous cells to suppress tumor suppressive
responses makes them addicted to the activity of specific
pathways that are otherwise redundant in normal cells,
thus opening up new therapeutic opportunities.
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